Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology ConferencePRNewsWire • 01/17/23
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem MeetingsPRNewsWire • 01/12/23
Actinium Highlights Survival Data in Relapsed/Refractory AML Patients with Prior Venetoclax Treatment and/or with a TP53 Mutation from the Actimab-A CLAG-M Combination Trial Oral Presentation at ASHPRNewsWire • 12/12/22
Actinium Pharmaceuticals, Inc. Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 NegativePRNewsWire • 12/08/22
Actinium Announces Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML in Phase 1 Actimab-A CLAG-M Combination TrialPRNewsWire • 11/03/22
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B CommercializationPRNewsWire • 11/02/22
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid LeukemiaPRNewsWire • 10/31/22
Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-APRNewsWire • 10/27/22
Actinium Bolsters its Senior Leadership Team Ahead of Upcoming Clinical Data for Iomab-BPRNewsWire • 10/25/22
Actinium to Present at the Cantor Fitzgerald Oncology, Hematology & HemeOnc ConferencePRNewsWire • 09/26/22
Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming MilestonesPRNewsWire • 09/21/22
Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/08/22
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully EngraftedPRNewsWire • 04/25/22
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTRPRNewsWire • 04/19/22
Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?InvestorPlace • 04/12/22